Sexually Transmitted Human Papillomavirus: Update in Epidemiology, Prevention, and Management.
Plotzker RE, Vaidya A, Pokharel U, Stier EA.
Infect Dis Clin North Am. 2023 Jun;37(2):289-310. doi: 10.1016/j.idc.2023.02.008.
Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.
Wei F, Georges D, Man I, Baussano I, Clifford GM.
Lancet. 2024 Aug 3;404(10451):435-444. doi: 10.1016/S0140-6736(24)01097-3.
Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies.
Liu Y, Ai H.
Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189192. doi: 10.1016/j.bbcan.2024.189192. Epub 2024 Sep 29.
Prevention and treatment of human papillomavirus in men benefits both men and women.
Zou K, Huang Y, Li Z.
Front Cell Infect Microbiol. 2022 Nov 24;12:1077651. doi: 10.3389/fcimb.2022.1077651. eCollection 2022.
Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline Update.
Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Kalicanin T, Krane JF, Lacchetti C, Moncur JT, Rocco JW, Schwartz MR, Seethala RR, Faquin WC.
Arch Pathol Lab Med. 2025 Jun 1;149(6):e115-e150. doi: 10.5858/arpa.2024-0388-CP.
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group.
N Engl J Med. 2007 May 10;356(19):1915-27. doi: 10.1056/NEJMoa061741.
Human Papillomavirus Vaccination and Actinic Keratosis Burden: The VAXAK Randomized Clinical Trial.
Wenande E, Hastrup A, Wiegell S, Philipsen PA, Thomsen NB, Demehri S, Kjaer SK, Haedersdal M.
JAMA Dermatol. 2025 Jun 1;161(6):605-614. doi: 10.1001/jamadermatol.2025.0531.
Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations.
Zigras T, Mayrand MH, Bouchard C, Salvador S, Eiriksson L, Almadin C, Kean S, Dean E, Malhotra U, Todd N, Fontaine D, Bentley J.
Curr Oncol. 2023 Jun 9;30(6):5652-5679. doi: 10.3390/curroncol30060425.
A multiplex RPA-CRISPR/Cas12a-based POCT technique and its application in human papillomavirus (HPV) typing assay.
Liu Y, Chao Z, Ding W, Fang T, Gu X, Xue M, Wang W, Han R, Sun W.
Cell Mol Biol Lett. 2024 Mar 8;29(1):34. doi: 10.1186/s11658-024-00548-y.
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Zhu FC, Zhong GH, Huang WJ, Chu K, Zhang L, Bi ZF, Zhu KX, Chen Q, Zheng TQ, Zhang ML, Liu S, Xu JB, Pan HX, Sun G, Zheng FZ, Zhang QF, Yi XM, Zhuang SJ, Huang SJ, Pan HR, Su YY, Wu T, Zhang J, Xia NS.
Lancet Infect Dis. 2023 Nov;23(11):1313-1322. doi: 10.1016/S1473-3099(23)00275-X. Epub 2023 Jul 17.
